Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s “Doctored.” ...

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

Cancer researcher Karen Sfanos says she is 'terrified' of the impact of cuts to NIH funding that supports vital biomedical ...

Finding a clinical trial that is a good fit can be challenging. Here's how to get the most out of your clinical trial search.

Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, expectations were $-1.07. Operator: Good day, and thank you for standing by.

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...

Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...